Fwd: Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Fri, Aug 1, 2008 at 4:32 PM
Subject: Effectiveness of service screening: a case-control study to assess breast cancer mortality reduction.
To: mesothelioma77@gmail.com


[1]Br J Cancer. 2008 Aug 5; 99(3): 423-7
Puliti D, Miccinesi G, Collina N, De Lisi V, Federico M, Ferretti S, Finarelli AC, Foca F, Mangone L, Naldoni C, Petrella M, Ponti A, Segnan N, Sigona A, Zarcone M, Zorzi M, Zappa M, Paci E

The aim of this study was the evaluation of the impact of service screening programmes on breast cancer mortality in five regions of Italy. We conducted a matched case-control study with four controls for each case. Cases were defined as breast cancer deaths occurred not later than 31 December 2002. Controls were sampled from the local municipality list and matched by date of birth. Screening histories were assessed by the local, computerised, screening database and subjects were classified as either invited or not-yet-invited and as either screened or unscreened. There were a total of 1750 breast cancer deaths within the 50 to 74-year-old breast cancer cases and a total of 7000 controls. The logistic conditional estimate of the cumulative odds ratios comparing invited with not-yet-invited women was 0.75 (95% CI: 0.62-0.92). Restricting the analyses to invited women, the odds ratio of screened to never-respondent women corrected for self-selection bias was 0.55 (95% CI: 0.36-0.85). The introduction of breast cancer screening programmes in Italy is associated with a reduction in breast cancer mortality attributable to the additional impact of service screening over and above the background access to mammography.British Journal of Cancer (2008) 99, 423-427. doi:10.1038/sj.bjc.6604532 www.bjcancer.com.



___
Source: http://www.hubmed.org/display.cgi?uids=18665188
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 Links for Aseanface Humor

http://www.aseanface.com/social_blog_view.php?scm_id=294&sb_id=247 

http://www.aseanface.com/social_blog_view.php?scm_id=294&sb_id=236

http://www.aseanface.com/display_blog.php?sgc_id=37

http://www.aseanface.com/social_blog_view.php?scm_id=307&sb_id=229

http://www.aseanface.com/social_blog_view.php?scm_id=307&sb_id=225

http://www.aseanface.com/social_blog_view.php?scm_id=307&sb_id=219

http://www.aseanface.com/social_blog_view.php?scm_id=294&sb_id=197

http://www.aseanface.com/display_blog.php?sgc_id=35

 

Poems URL Links

http://www.aseanface.com/social_blog_view.php?scm_id=294&sb_id=247

http://www.aseanface.com/social_blog_group_show.php?sbg_id=6

Fwd: Return to Work After Early-stage Breast Cancer: A Cohort Study into the Effects of Treatment and Cancer-related Symptoms.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Aug 3, 2008 at 8:08 AM
Subject: Return to Work After Early-stage Breast Cancer: A Cohort Study into the Effects of Treatment and Cancer-related Symptoms.
To: mesothelioma77@gmail.com


[1]J Occup Rehabil. 2008 Aug 1;
Balak F, Roelen CA, Koopmans PC, Ten Berge EE, Groothoff JW

Introduction Earlier diagnosis and better treatment have increased the survival rates of cancer patients. This warrants research on return to work of cancer survivors. What is the return to work rate following early-stage breast cancer? What is the effect of the type of treatment and cancer-related symptoms on return to work? Methods Our occupational health department registers sickness absence of about 50,000 employees. In the period 2001-2005 we counted 154 cases of newly diagnosed breast cancer of which 72 were eligible for analysis. In these women, return to work was followed for 24 months after diagnosis and linked to the type of treatment and cancer-related symptoms. Results The mean duration of absence with early-stage breast cancer was 11.4 +/- 5.5 months; 35% of patients were absent longer than one year and 4 patients did not return to work within two years after diagnosis. The duration of absence depended on the type of treatment and was significantly longer in patients who underwent chemotherapy (hazard rate [HR] = 0.31; 95% confidence interval [CI] = 0.12-0.81) or multimodal treatment (HR = 0.24; 95% CI = 0.10-0.54). Women started working about 4 months after the end of therapy irrespective of the type of treatment. At that moment, reaching above shoulder level was impaired in 11 patients (15%) which significantly delayed partial return to work (HR = 0.48; 95% CI = 0.23-0.98) but not full return to work (HR = 0.63; 95% CI = 0.31-1.26). Fatigue was reported by 9 patients (13%) and neither postponed partial return to work nor full return to work. Conclusions The time taken to return to work after early-stage breast cancer was principally determined by the type of treatment.



___
Source: http://www.hubmed.org/display.cgi?uids=18670868
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc